Self-monitoring of blood glucose in association with glycemic control in newly diagnosed non-insulin-treated diabetes patients: a retrospective cohort study
| Autor: | Chew-Teng Kor, Pei-Yung Liao, Jiun-Yi Wang, Hon-Ke Sia, Shih-Te Tu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Blood Glucose
Male medicine.medical_specialty Longitudinal study endocrine system diseases medicine.medical_treatment Science Taiwan 030209 endocrinology & metabolism Diseases Type 2 diabetes Glycemic Control Article 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Endocrinology Medical research Internal medicine Medicine Humans Hypoglycemic Agents Insulin 030212 general & internal medicine Longitudinal Studies Generalized estimating equation Glycemic Retrospective Studies Glycated Hemoglobin Multidisciplinary business.industry Medical record Blood Glucose Self-Monitoring Health care nutritional and metabolic diseases Retrospective cohort study medicine.disease chemistry Diabetes Mellitus Type 2 Female Glycated hemoglobin business |
| Zdroj: | Scientific Reports Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021) |
| ISSN: | 2045-2322 |
| Popis: | The benefits of self-monitoring of blood glucose (SMBG) on glycemic control among type 2 diabetes (T2DM) patients not receiving insulin remains controversial. This study aimed to examine the association between SMBG and glycemic control in these patients. This retrospective longitudinal study enrolled 4987 eligible patients from a medical center in Taiwan. Data were collected from electronic medical records at 0 (baseline), 3, 6, 9, and 12 (end-point) months after enrollment. Patients were assigned to the early SMBG group or to the non-user group depending on whether they performed SMBG at baseline. Differences in glycated hemoglobin (HbA1c) reduction between groups at each time-point were assessed using SMBG group-by-time interaction in generalized estimating equations models, which were established using backward elimination method for multivariate regression analysis. Subgroup analyses for patients using non-insulin and insulin secretagogues were performed additionally. The estimated maximal difference in HbA1c reduction between groups (early SMBG users vs. non-users) was 0.55% at 3 months. Subgroup analyses showed maximal differences of 0.61% and 0.52% at 3 months in the non-insulin and insulin secretagogues groups, respectively. SMBG group-by-time interaction was statistically significant at 3 months and lasted for 12 months. The finding suggests that performing SMBG at disease onset was positively associated with better glycemic control in newly diagnosed non-insulin-treated T2DM patients, regardless whether non-insulin secretagogues or insulin secretagogues were used. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|